Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1Phase 1 1

Status

Completed 2Recruiting 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 3Myeloid 3Gastrointestinal 3Thoracic 1Other hematologic neoplasm 1NET 1Lymphoid 1Genitourinary 1Endocrine 1Dermatologic 1

Conditions

Colorectal Neoplasms 1464Pancreatic Neoplasms 833Stomach Neoplasms 693Carcinoma, Hepatocellular 648Carcinoma, Non-Small-Cell Lung 543Neoplasms 459Breast Neoplasms 369Ovarian Neoplasms 338Neoplasm Metastasis 337Colonic Neoplasms 332Esophageal Neoplasms 297Liver Neoplasms 266Melanoma 255Lung Neoplasms 246Squamous Cell Carcinoma of Head and Neck 210Cholangiocarcinoma 181Carcinoma, Renal Cell 181Prostatic Neoplasms 175Head and Neck Neoplasms 172Triple Negative Breast Neoplasms 163Rectal Neoplasms 160Endometrial Neoplasms 160Uterine Cervical Neoplasms 155Gastrointestinal Neoplasms 142Urinary Bladder Neoplasms 139Biliary Tract Neoplasms 136Gastrointestinal Stromal Tumors 108Sarcoma 105Esophageal Squamous Cell Carcinoma 102Small Cell Lung Carcinoma 95

Interventions

nilotinib 1Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Piebaldism × Gastrointestinal × Clear all
NCT06805825 2025-09-23

A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit

Novelty Nobility, Inc.

Phase 1 Recruiting
67 enrolled
DermatologicEndocrineGastrointestinalGenitourinaryNETSarcomaThoracic

Uveal Melanoma, Carcinoma, Renal Cell, Carcinoma, Adenoid Cystic, Piebaldism, Neuroendocrine Tumors, Gastrointestinal Stromal Tumors, Small Cell Lung Carcinoma

NCT01735955 2024-02-08

Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study

Novartis

Phase 4 Completed
57 enrolled 8 charts
GastrointestinalLymphoidMyeloidOther hematologic neoplasmSarcoma

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Piebaldism, Gastrointestinal Stromal Tumors, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00237185 2014-08-19

A Study of the Efficacy and Safety of Imatinib Mesylate in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing C-kit Gene

Novartis

Phase 2 Completed
148 enrolled 17 charts
GastrointestinalSarcoma

Piebaldism, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡